The possible mechanisms of action of progestins on endometrial adenocarcinoma.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D001706:Biopsy; D001772:Blood Cell Count; D001797:Blood Protein Electrophoresis; D004717:Endometrium / Q000473:pathology; D004967:Estrogens / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors; D006065:Gonadotropins, Pituitary / Q000037:antagonists & inhibitors; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors; D008214:Lymphocytes; D008525:Medroxyprogesterone / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D010166:Palliative Care; D011276:Pregnanediol / Q000652:urine; D012075:Remission, Spontaneous; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy*
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D004967:Estrogens; D006065:Gonadotropins, Pituitary; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone; D011276:Pregnanediol